Anvik Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.10 M
- Paid Up Capital ₹ 2.10 M
- Company Age 14 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.00 M
- Revenue Growth 0.04%
- Profit Growth -37.04%
- Ebitda 10.37%
- Net Worth 0.96%
- Total Assets -6.13%
About Anvik Biotech
Anvik Biotech Private Limited (ABPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 September 2010 and has a history of 14 years and four months. Its registered office is in Sonipat, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.10 M and a paid-up capital of Rs 2.10 M.
The company has closed loans amounting to ₹5.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Anju Pruthi and Nishchal Pruthi serve as directors at the Company.
Company Details
-
Location
Sonipat, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999HR2010PTC092954
-
Company No.
208809
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Sep 2010
-
Date of AGM
23 Jul 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Anvik Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anju Pruthi
|
Director | 22-Mar-2018 | Current |
|
Nishchal Pruthi
|
Director | 27-Sep-2010 | Current |
Financial Performance of Anvik Biotech.
Anvik Biotech Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.04% increase. The company also saw a substantial fall in profitability, with a 37.04% decrease in profit. The company's net worth moved up by a moderate rise of 0.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anvik Biotech?
In 2023, Anvik Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Zen Life Pharmacia Private LimitedNishchal Pruthi is a mutual person
Charges (Loans)
₹0
₹5.00 M
Charges Breakdown by Lending Institutions
- Punjab National Bank : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Feb 2013 | Punjab National Bank | ₹2.50 M | Satisfied |
| 22 Jan 2013 | Punjab National Bank | ₹2.50 M | Satisfied |
How Many Employees Work at Anvik Biotech?
Unlock and access historical data on people associated with Anvik Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anvik Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anvik Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
